erythromycin has been researched along with quercetin in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 8 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Dutour, R; Poirier, D | 1 |
| Adebesin, AM; Falck, JR; Fischer, R; Konkel, A; Lossie, J; Paudyal, MP; Puli, N; Schunck, WH; Vijaykumar, J; Wesser, T; Westphal, C; Zhu, C | 1 |
| Abreu, AC; Borges, A; Mcbain, AJ; Saavedra, MJ; Salgado, AJ; Serra, SC; Simões, M | 1 |
| Abreu, AC; Saavedra, MJ; Simões, LC; Simões, M | 1 |
| Chłopecka, M; Dziekan, N; Karlik, W; Mendel, M | 1 |
| Hu, ZQ; Li, YJ; Li, ZG; Song, SD; Tang, HF; Wang, XF; Yan, CG; Zhang, ZW | 1 |
1 review(s) available for erythromycin and quercetin
| Article | Year |
|---|---|
Inhibitors of cytochrome P450 (CYP) 1B1.
Topics: Cytochrome P-450 CYP1B1; Cytochrome P-450 Enzyme Inhibitors; Dose-Response Relationship, Drug; Humans; Molecular Structure; Structure-Activity Relationship | 2017 |
9 other study(ies) available for erythromycin and quercetin
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Development of Robust 17(
Topics: Administration, Oral; Animals; Anti-Arrhythmia Agents; Arachidonic Acids; Dose-Response Relationship, Drug; Drug Stability; Epoxide Hydrolases; Esterification; Hepatocytes; Humans; Male; Mice; Microsomes, Liver; Myocardial Infarction; Myocytes, Cardiac; Rats, Sprague-Dawley; Rats, Wistar | 2019 |
Combinatorial Activity of Flavonoids with Antibiotics Against Drug-Resistant Staphylococcus aureus.
Topics: Ampicillin; Anti-Bacterial Agents; Catechin; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Erythromycin; Flavonoids; Hesperidin; Humans; Microbial Sensitivity Tests; Oxacillin; Quercetin; Rutin; Staphylococcal Infections; Staphylococcus aureus; Tetracycline | 2015 |
Combinatorial approaches with selected phytochemicals to increase antibiotic efficacy against Staphylococcus aureus biofilms.
Topics: Anti-Bacterial Agents; Biofilms; Ciprofloxacin; Drug Synergism; Erythromycin; Flavonoids; Microbial Sensitivity Tests; Phytochemicals; Quercetin; Quinine; Staphylococcus aureus; Tetracycline | 2016 |
Interactions between erythromycin, flunixin meglumine, levamisole and plant secondary metabolites towards bovine gastrointestinal motility-in vitro study.
Topics: Abomasum; Animals; Apigenin; Cattle; Clonixin; Drug Interactions; Duodenum; Erythromycin; Female; Gastrointestinal Motility; In Vitro Techniques; Levamisole; Muscle Contraction; Muscle, Smooth; Oleanolic Acid; Quercetin; Secondary Metabolism; Triterpenes | 2018 |
Protective Effect of Quercetin in LPS-Induced Murine Acute Lung Injury Mediated by cAMP-Epac Pathway.
Topics: Acetylcysteine; Acute Lung Injury; Animals; Cell Line; Cyclic AMP; Erythromycin; Inflammation; Inflammation Mediators; Lipopolysaccharides; Lung; Mice; Protective Agents; Quercetin | 2018 |